Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

Dry Eye Clinical Trial

Official title:

Prospective Evaluation of the Efficacy and Safety of Topical Hydrocortisone Treatment on Clinical Signs and Symptoms of Dry Eye Disease Associated With Moderate Meibomian Gland Dysfunction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05159284
• Other study ID #: THEA_HLF_1/21
• Status: Recruiting
• Phase: Phase 4
• Start date: November 9, 2021
• Est. completion date: March 2025

Study information

• Verified date: March 2024
• Source: Laboratorios Thea, Spain
• Contact: Maria Beatriz Greaves, Dr
• Phone: +34934766810
• Email: maría.greaves[@]theapharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is assess the efficacy and safety of topical hydrocortisone (Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated with moderate meibomian gland dysfunction.

Description:

This is a prospective, interventional, randomized (1:1), single blind, of parallel groups and two treatment arms clinical trial (phase IV). All patients diagnosed with dry eye disease (DED) associated with moderate MGD may participate in the study if they meet all the selection criteria. Patients (or their representatives) will provide informed consent (IC) prior to the enrolment in the study and to the start of data collection. Patients must meet all the inclusion criteria and not meet any of the exclusion criteria.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Documented diagnosis of DE defined by TBUT value = 5 seconds and Schirmer I test value < 10 mm/5 min

3. Normal ophthalmic findings except dry eye disease and meibomian gland dysfunction

4. OSDI score > 23 (moderate symptoms)

5. Documented diagnosis of MGD grade 2 to 3

6. Patient who can understand the instructions and adhere to medications

7. Patient who receives complete information regarding the study objectives, authorize their participation in the study and sign an informed consent form before entering in the study

Exclusion Criteria:

1. Any contraindication or known allergies to Lephanet®, Thealoz Duo®, MGD Rx EyeBag® or Softacort®

2. Ocular surgery in the past 6 months

3. Ocular hypertension or glaucoma

4. Cicatricial MGD

5. Atopic condition including ocular allergy

6. Suspect demodex lid infestation as evidenced by the presence of collarettes

7. Intraocular inflammation

8. Confirmed infection with COVID-19 in the last 3 months

9. Systemic autoimmune disorder

10. Use of contact lenses during the month prior to inclusion in the study or during the study

11. Punctal occlusion

12. Intraocular pressure > 22 mmHg

13. Patient who has received topical or systemic anti-inflammatory treatments including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDS) within 3 months prior to be included in the study or with a prescription for receiving topical / systemic anti-inflammatory treatments for the next 3 months

14. In the investigator´s opinion, use of systemic medications that could affect the function of the meibomian gland and tear production within 3 months prior to be included in the study

15. Any ocular or systemic disease known to affect the tear film other than MGD

16. Patient with any situation or state that in the opinion of the investigator discourages their participation in the study

17. Patient participating in any other interventional or non-interventional study or who have participated in another study within 30 days prior to inclusion in this study

18. Women who are pregnant, planning to become pregnant or breastfeeding

19. Patient who will not be able to complete the study (e.g., not willing to attend the follow-up visits, way of life interfering with compliance)

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Meibomian Gland Dysfunction

Intervention

Drug:
• Hydrocortisone Ophthalmic
1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.

Device:
• MGD Rx EyeBag® eyelid warming device
Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
• Lephanet® lid wipes
Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
• Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%
Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.

Locations

Country	Name	City	State
Spain	Hospital La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Laboratorios Thea, Spain

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy endpoint: Change from baseline in Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) at 14 days	Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) calculated by the sum of the Visual Analogue scale (VAS) score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in the following symptoms: itching, dry eye sensation, burning, foreign body sensation and ocular redness.	Day 0 and Day 14
Primary	Safety endpoint: Incidence of increased intraocular pressure and change from baseline at Day 0, Day 14, Day 28 and Day 84	Mean of 3 measures of intraocular pressure measured with Goldmann tonometer in each eye on Day 0, Day 14, Day 28 and Day 84. Increased intraocular pressure defined as >21 mmHg.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire at Day 14, Day 28 and Day 84	12-item questionnaire related to vision-related function, ocular symptoms, and environmental triggers of dry eye. Response on a 0 to 4 scale that ranges from "none of the time" to "all of the time". The final score is calculated by multiplying the sum of all the scores by 25 and then dividing the total by the number of questions answered. Scores range from 0 to 100 with 0 to 12 representing normal, 13 to 22 mild DED, 23 to 32 moderate DED, and 33 severe DED	Day 0, Day 14, Day 28 and Day 84.
Secondary	Change from baseline in Meibomian Gland Dysfunction Dry Eye symptom score at Day 14, Day 28 and Day 84	Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) calculated by the sum of the VAS score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in the following symptoms: itching, dry eye sensation, burning, foreign body sensation and ocular redness.	Day 0, Day 14, Day 28 and Day 84.
Secondary	Change from baseline in ocular symptoms Visual Analogue scale (VAS) questionnaire at Day 14, Day 28 and Day 84	VAS score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in each of the following symptoms: itching, dry eye sensation, burning, foreign body sensation, ocular redness, ocular fatigue, and blurry vision.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in hyperemia score (McMonnies-Chapman scale) at Day 14, Day 28 and Day 84.	Inferior conjunctival hyperemia will be estimated by comparison with the photographic conjunctival hyperemia reference scale covering six grades, with highest grade as worst hyperemia.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Tear break up time (TBUT) at Day 14, Day 28 and Day 84	Number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film observed with slit-lamp after instillation of fluorescein. A TBUT under 10 seconds is considered abnormal	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in corneal and conjunctival staining with fluorescein (Oxford grading scale) at Day 14, Day 28 and Day 84	After instillation of fluorescein in conjunctival sac a comparison to the Oxford chart panels A to E, with E being the worst outcome.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in corneal and conjunctival staining with lissamine green (Van Bijsterveld scale) at Day 14, Day 28 and Day 84	Scoring system that divides the ocular surface into three zones: nasal bulbar conjunctiva, temporal bulbar conjunctiva, and cornea. Each zone is evaluated on a scale of 0 to 3, with 0 indicating no staining and 3 indicating confluent staining; the maximum possible worse outcome score with this system is 9.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in meniscus height at Day 14, Day 28 and Day 84	Measured with anterior segment optical coherence tomography. The lower the tear meniscus height the worst outcome.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Schirmer I test at Day 14, Day 28 and Day 84	Folded edge Schirmer strip is placed over the rim of the lower eyelid and the eyes are then lightly closed. The amount of wetting after 5 minutes on the strip is measured in mm. Normal more than 10 mm / 5 min	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in MGD grading at Day 14, Day 28 and Day 84	Grading of MGD: 0 to 4 where 0 is no meibomian gland dropout and expressed meibum with clear appearance and 4 is with gland dropout of more than half the lid margin or complete keratinization of the ducts and no expression of meibum. Higher grade is a worse outcome.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in lid abnormalities at Day 14, Day 28 and Day 84	Lid margin irregularity (presence or absence), thickness, and plugging of the meibomian orifices. A scale from 0 to 2, with 0 = no findings, 1 = mild findings, and 2 = severe findings.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Eyelid telangiectasia score at Day 14, Day 28 and Day 84	Eyelid telangiectasia score from 0 to 3, where 0 is no findings and 3 is severe findings.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Lissamine green staining score at Day 14, Day 28 and Day 84	Mean of longitudinal staining of upper lid margin after instilation with lissamine green graded from 0 to 3 and sagittal staining graded from 0 to 3 estimated by comparison with standard chart. Higher grade is a worse outcome.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in Meibomian gland expressibility score at Day 14, Day 28 and Day 84	Express each of 5 glands in temporal, central and lower lid and grade each gland on a scale from 0 to 3, with 3 = clear liquid secretion, 2 = cloudy liquid secretion, 1 = inspissated / toothpaste consistency, and 0 = no secretion. Total score range from 0 to 45. A lower grade is a worse outcome.	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in tear inflammatory cytokines at Day 14	Levels of 8 inflammatory cytokines in tears will be determined 2 micro liter samples taken from each eye.	Day 0 and Day 14.
Secondary	Incidence of adverse events and serious adverse events occurred during the study.	Report of any untoward medical occurrence in a patient during the study	Day 0, Day 14, Day 28 and Day 84
Secondary	Change from baseline in ETDRS visual acuity at Day 14, Day 28 and Day 84	Best corrected visual acuity in each eye measured with the ETDRS optotype.	Day 0, Day 14, Day 28 and Day 84